International Journal of Clinical Research

Objective To explore the value of recombinant human interferon alb atomization inhalation in the treatment of herpetic pharyngitis in children. Methods Children with herpetic pharyngitis in our hospital from January 2023 to January 2024 were selected as the research subjects (100 cases). Due to differences in clinical treatment methods for children, those who received recombinant human interferon alb atomization inhalation were included in the study group (50 cases), and those who received conventional treatment were included in the reference group (50 cases). The two groups were compared in terms of treatment effectiveness, immune function indicators, and inflammatory factor levels. Results The treatment effectiveness of the children was compared, and the study group was higher than the reference group; the immune function indicators of the children were compared, and the study group was higher than the reference group; the inflammatory factor levels of the children were compared, and there were significant differences between the two groups, and the study group was better than the reference group (P < 0.05). Conclusion The clinical application of recombinant human interferon alb atomization inhalation in the treatment of herpetic pharyngitis in children is ideal, which can comprehensively improve the treatment efficiency, enhance the immune function of children, relieve inflammatory response, effectively promote recovery, shorten the symptom recovery time and hospitalization time, and it is recommended to promote its application.

Herpetic pharyngitis in children; Recombinant human interferon alb; Atomization inhalation; Immune function; Inflammatory factors